Zituvimet is a prescription medication combining sitagliptin and metformin hydrochloride, used to improve glycemic control in adults with type 2 diabetes.
Zituvimet is a prescription medication combining sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride, a biguanide. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The medication is available in standard and extended-release (XR) formulations.
On this page, you will find patient medication guides, instructions for use, and full prescribing information for Zituvimet products. These documents provide essential details on dosage, administration, contraindications, and potential adverse reactions. Always consult a healthcare provider for medical advice.
Latest manuals from manuals+ curated for this brand.
Common questions about manuals, registration, and support for this brand.
Zituvimet is a prescription medication combining sitagliptin and metformin hydrochloride, used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.
Zituvimet should generally be taken orally twice daily with meals. The extended-release version (Zituvimet XR) is typically taken once daily with a meal. Always follow the specific dosage instructions provided by your healthcare provider.
The active ingredients in Zituvimet are sitagliptin, a DPP-4 inhibitor, and metformin hydrochloride, a biguanide.
Yes, Zituvimet carries a boxed warning for lactic acidosis associated with metformin. Patients should consult their prescribing information and seek immediate medical attention if they experience unusual tiredness, difficulty breathing, or severe abdominal pain.